Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ELB139

Phase 2Small molecule

ELB139 is one of 32 small molecule programs targeting Panic Disorder. It is currently in Phase 2.

1

Indications

1

Total Trials

0

Active Trials

31

Competitors

Pipeline

Status by Indication[3][1]

Indication

Panic DisorderActive, not recruiting

Panic DisorderPhase 2

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Panic Disorder

#DrugCompanyPhaseTrials

Brintellix

Cymbalta

Alnylam Pharmaceuticals

Atarax

Paxil CR

Paxil

SSebela Pharmaceuticals Development LLC

Xanax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Lexapro

Celexa

Klonopin

EEngelhard Arzneimittel GmbH & Co.KG

Zoloft

VViatris Specialty LLC

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Panic Disorder1 trial

ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by CO2 Inhalation After a Single Dose and One Week of Treatment

Terminated·Eelbion AG·Phase 2·NCT00322803·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ELB139. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ELB139 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ELB139. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — elbion AG company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Eelbion AG

Related News